市場調查報告書
商品編碼
1494844
2030 年冷凍電子顯微鏡市場預測:按產品類型、方法、奈米製劑、電壓、技術、應用和地區進行的全球分析Cryo-Electron Microscopy Market Forecasts to 2030 - Global Analysis By Product Type, Method, Nano Formulations, Voltage, Technology, Application and By Geography |
根據 Stratistics MRC 的數據,2024 年全球冷凍電鏡市場規模為 14.2 億美元,預計到 2030 年將達到 30.5 億美元,預測期內年複合成長率為 13.60%。
冷凍電子顯微鏡使我們能夠以前所未有的細節觀察生物分子結構,徹底改變了結構生物學領域。該技術使用低溫下的電子顯微鏡快速冷凍樣品並在自然狀態下進行成像。冷凍電子顯微鏡無需化學固定或染色即可獲得原始生物大分子的高解析度影像。此外,冷凍電子顯微鏡捕捉動態分子結構的能力使得生物化學、藥理學和病毒學領域的重大進展成為可能。
世界衛生組織(WHO)表示,獲得基本藥物是一項基本人權,確保這些藥物的公平分配和可負擔性對於實現全球健康目標至關重要。
對藥物開發和發現的需求不斷增加
冷凍電子顯微鏡已成為製藥業中先導化合物化合物最佳化、藥物標靶結構闡明和合理藥物設計的強大工具。以近原子解析度觀察動態蛋白質-藥物相互作用和大分子複合物的能力為潛在治療藥物的作用機制提供了重要的見解。此外,隨著藥物發現管道轉向更多關注生物製藥、膜蛋白和困難的藥物靶標,冷凍電鏡服務和專業知識的需求量很大,從而推動了市場擴張。
資料分析和樣品製備的複雜性
冷凍電鏡樣品的網格、玻璃化和成像條件的準備需要特定的知識和工具。對於沒有經驗的使用者來說,進入該領域的主要障礙是需要精通資料分析和冷凍電子顯微鏡技術,以及與樣品製備相關的費力且複雜的工作流程。此外,冷凍電子顯微鏡實驗會產生大量原始資料,需要複雜的影像處理演算法和可靠的計算基礎設施來進行資料分析和結構細化。
硬體和軟體技術進步
公司有很多機會發揮創意並提供尖端的冷凍電子顯微鏡硬體和軟體。這包括開發和製造具有改進的自動化、靈敏度和解析度的下一代電子顯微鏡。此外,對使用者友善的影像處理、資料擷取和結構分析軟體平台的需求也日益成長。這使軟體開發人員有機會開發高效且易於使用的工具,以改善使用者體驗並簡化冷凍電子顯微鏡工作流程。
市場飽和與競爭壓力
提供冷凍電子顯微鏡解決方案的製造商、服務供應商和研究機構的數量不斷增加,使得冷凍電子顯微鏡市場變得擁擠。價格戰、利潤空間縮小以及冷凍電子顯微鏡產品和服務的商品化可能是激烈競爭的後果。此外,中小企業與規模更大、實力更雄厚的公司競爭將變得更加困難,並且由於市場飽和,該行業可能會經歷收益成長放緩、盈利下降和行業整合。
冷凍電子顯微鏡 (cryo-EM) 市場受到了 COVID-19 大流行的各種影響。疫情最初擾亂了供應鏈、製造業務和研究活動,導致設備安裝、服務合約和合作計劃延遲;增加了對法律的需求。由於迫切需要了解 SARS-CoV-2 的分子機制並促進疫苗、治療和診斷的開發,冷凍電子顯微鏡已廣泛應用於 COVID-19 研究。此外,向遠端工作和虛擬協作的轉變加速了基於雲端基礎的冷凍電鏡資料分析平台和遠端存取解決方案的採用。
脂質奈米顆粒製劑(LNFS)產業預計將在預測期內成為最大的產業
脂質奈米顆粒製劑 (LNF) 在冷凍電子顯微鏡 (Cryo-EM) 領域佔據最大的市場佔有率,因為它們廣泛用於傳遞遺傳物質,例如用於疫苗和治療的 mRNA。這些脂質奈米顆粒可以使用冷凍電子顯微鏡 (Cryo-EM) 進行高解析度成像,提供有關其尺寸、成分和結構完整性的資訊。此外,先進的藥物開發需要使用脂質體形成因子(LNF),因為它們具有生物相容性以及封裝和保護脆弱有效負載的能力。
穿透式電子顯微鏡(TEM)產業預計在預測期內年複合成長率最高
在冷凍電子顯微鏡 (Cryo-EM) 市場中,穿透式電子顯微鏡(TEM) 領域預計將出現最高的年複合成長率。對生物大分子的高解析度成像和結構分析的需求正在不斷增加,而這種成長是由材料科學、結構生物學和藥物發現的進步的需求所推動的。此外,尋求了解複雜生物過程和分子結構的研究人員發現 TEM 能夠產生原子級詳細的原子態影像,尤其是與低溫電子顯微鏡結合使用時,這一點非常寶貴。
冷凍電子顯微鏡(cryo-Electronic Microscopy)市場以主要行業參與者的集中、堅實的研究基礎設施以及對最尖端科技的大規模投資為主導,北美佔據壓倒性的佔有率。該地區高度重視科學技術,公共和私營部門大力資助,推動冷凍電子顯微鏡在材料科學、製藥和結構生物學等多個領域的應用。此外,頂尖學術機構和生物製藥公司的集中促進了協作和創造力,鞏固了北美作為冷凍電子顯微鏡產品市場領導的地位。
由於工業化的快速發展、研發支出的增加以及各行業擴大採用最尖端科技,冷凍電子顯微鏡 (Cryo-EM) 市場正以亞太地區最高的年複合成長率成長。該地區生物技術和製藥行業的成長以及政府支持科學研究和創新的舉措不斷增加,推動了對冷凍電子顯微鏡解決方案的需求。此外,大量高技能研究人員和科學家的存在以及與國際組織和學術機構的合作進一步推動了亞太地區冷凍電子顯微鏡市場的成長。
According to Stratistics MRC, the Global Cryo-Electron Microscopy Market is accounted for $1.42 billion in 2024 and is expected to reach $3.05 billion by 2030 growing at a CAGR of 13.60% during the forecast period. Due to its ability to enable researchers to see bio molecular structures in unprecedented detail, cryo-electron microscopy, or cryo-EM, has completely changed the field of structural biology. Using an electron microscope at extremely low temperatures, samples are imaged using this technique, which involves rapidly freezing them to preserve their natural state. High-resolution images of biological macromolecules in their natural habitat can be obtained using cryo-EM without the need for chemical fixation or staining. Moreover, significant advancements in the domains of biochemistry, pharmacology, and virology have resulted from its capacity to capture dynamic molecular structures.
According to the World Health Organization (WHO), access to essential medicines is a fundamental human right, and ensuring equitable distribution and affordability of these medicines is critical for achieving global health goals.
Growing need for drug development and discovery
Cryo-EM has become a potent tool in the pharmaceutical industry for lead optimization, structural elucidation of drug targets, and rational drug design. The capacity to observe dynamic protein-drug interactions and macromolecular complexes at near-atomic resolution provides significant insight into the potential therapeutics' mechanisms of action. Additionally, Cryo-EM services and expertise are in high demand as drug discovery pipelines shift to focus more on biologics, membrane proteins, and difficult drug targets, which is driving market expansion.
Complexity of data analysis and sample preparation
The preparation of grids, vitrification, and imaging conditions for cryo-EM samples necessitates specific knowledge and tools. A major barrier to entry for inexperienced users is the laborious and complicated workflows involved in sample preparation, in addition to the requirement for proficiency in data analysis and cryo-EM techniques. Furthermore, cryo-EM experiments produce massive amounts of raw data, which calls for sophisticated image processing algorithms and a reliable computing infrastructure for data analysis and structural refinement.
Technological progress in hardware and software
There are many chances for businesses to be creative and provide cutting-edge cryo-EM hardware and software. This involves developing and producing next-generation electron microscopes with enhanced automation, sensitivity, and resolution. Moreover, there is a growing need for user-friendly software platforms for image processing, data acquisition, and structural analysis. This presents opportunities for software developers to create tools that are efficient and easy to use, which can improve the user experience and streamline the cryo-EM workflow.
Market saturation and competitive pressures
There are a growing number of manufacturers, service providers, and research institutions offering cryo-EM solutions, which is congesting the cryo-EM market. Price wars, shrinking profit margins, and the commoditization of cryo-EM goods and services are possible outcomes of fierce competition. Additionally, the industry may experience slower revenue growth, lower profitability, and more industry consolidation as a result of market saturation, as smaller firms find it more difficult to compete with more established, larger firms.
The cryo-electron microscopy (cryo-EM) market has been impacted by the COVID-19 pandemic in a number of ways. The pandemic increased demand for cryo-EM in researching the virus's structure, host interactions, and drug development, even though it initially disrupted supply chains, manufacturing operations, and research activities, causing delays in instrument installations, service contracts, and cooperative projects. Cryo-EM has become widely used in COVID-19 research due to the pressing need to comprehend the molecular mechanisms of SARS-CoV-2 and expedite the development of vaccines, therapeutics, and diagnostics. Moreover, the adoption of cloud-based cryo-EM data analysis platforms and remote access solutions has been accelerated by the shift towards remote work and virtual collaboration.
The Lipid Nanoparticle Formulations (LNFS) segment is expected to be the largest during the forecast period
Due to their extensive application in the delivery of genetic materials like mRNA for vaccines and therapeutics, Lipid Nanoparticle Formulations (LNFs) command the largest market share in cryo-electron microscopy (Cryo-EM). These lipid nanoparticles can be imaged at high resolution using cryo-electron microscopy (Cryo-EM), providing information about their size, composition, and structural honesty. Additionally, advanced pharmaceutical development requires the use of liposome-forming factors (LNFs) due to their biocompatibility and capacity to encapsulate and safeguard delicate payloads.
The Transmission Electron Microscopy (TEM) segment is expected to have the highest CAGR during the forecast period
The transmission electron microscopy (TEM) segment is expected to have the highest CAGR in the cryo-electron microscopy (Cryo-EM) market. The need for high-resolution imaging and structural analysis of biological macromolecules is growing, and this growth is being driven by the need to advance materials science, structural biology, and drug discovery. Furthermore, researchers attempting to comprehend intricate biological processes and molecular structures find that TEM is invaluable due to its capacity to produce detailed images at the atomic level in their native state, especially when used in conjunction with cryo-TEM.
The market for cryo-electron microscopy, or cryo-EM, is dominated by North America due in large part to the region's concentration of major industry players, solid infrastructure for research, and large investments in cutting-edge technology. The region's emphasis on science and technology, along with strong funding initiatives from both public and private entities, drives advancements in the use of cryo-EM in a variety of fields, such as materials science, pharmaceuticals, and structural biology. Moreover, the concentration of top academic institutions and biopharmaceutical firms encourages cooperation and creativity, which strengthens North America's position as the market leader for cryo-EM products.
The cryo-electron microscopy (Cryo-EM) market is growing at the highest CAGR in the Asia-Pacific region due to rapid industrialization, rising R&D spending, and a growing uptake of cutting-edge technologies in a variety of industries. The demand for cryo-EM solutions is driven by the region's growing biotechnology and pharmaceutical industries as well as growing government initiatives to support scientific research and innovation. Additionally, cryo-EM market growth in the Asia-Pacific region is further accelerated by the presence of a large pool of highly skilled researchers and scientists, as well as partnerships with international organizations and academia.
Key players in the market
Some of the key players in Cryo-Electron Microscopy market include Charles River Laboratories, Hitachi High-Technologies Corporation, Intertek Group Plc, Caliber Imaging & Diagnostics, Lasertec Corporation, HORIBA, Ltd, Olympus Corporation, Gatan, Inc., JEOL Ltd, Oxford Instruments, Nikon Instruments Inc, Keyence Corporation, Helmut Hund Gmbh, Danaher, Creative Biostructure, ZEISS International and Thermo Fisher Scientific.
In May 2024, Intertek announced an agreement to acquire Base Metallurgical Laboratories and Base Met Labs US on Monday, which provides metallurgical testing services within the minerals sector in North America, for an undisclosed sum. The AIM-traded firm said the acquisition came ahead of expected heightened demand for diverse energy sources and minerals to sustain a growing global population.
In May 2024, Hitachi High-Tech and Roche have extended their partnership, committing to at least 10 years of additional collaboration. Bringing together the companies' expertise and track record in diagnostics innovation, engineering and manufacturing, the renewed contract further strengthens the two companies' long lasting partnership.
In February 2024, Charles River Laboratories International, Inc. announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, providing clients access to Wheeler's Portable CMC platform.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.